Singapore’s factory output surged 14.3% year-on-year in November 2025, marking the third consecutive month of expansion. The growth was driven by a remarkable 124.3% surge in pharmaceutical production, cementing the biomedical sector’s dominance in the city-state’s economic recovery.
🔥 Quick Facts
- November 2025 output growth: 14.3% year-on-year, beating forecasts of 14.2%
- Pharmaceutical surge: 124.3% growth in pharma production after October’s 122.9% increase
- Biomedical cluster: Output jumped 79.3%, leading overall manufacturing gains
- Third straight month: Singapore’s factory output expands for third consecutive month
Singapore’s Pharma Boom Transforms Manufacturing Sector
Intuit emerges as best software stock for 2026 while stock crashes to bargain levels analysts didn’t expect
2026 tax brackets shock Americans with hidden paycheck truth nobody expected
The biomedical manufacturing cluster has become the engine of Singapore’s factory growth. Pharmaceutical production surged 124.3% in November following an equally impressive 122.9% jump in October. This sustained momentum reflects increased production of active pharmaceutical ingredients (APIs), positioning Singapore as a global pharmaceutical powerhouse. The medical technology segment also contributed meaningfully to the overall biomedical expansion of 79.3%.
Outside the volatile biomedical sector, Singapore’s general manufacturing contracted year-on-year. The general manufacturing cluster declined 8.8% from January through November 2025 compared to the same period a year ago. This indicates that growth is heavily concentrated in the biomedical segment rather than broad-based across all manufacturing types.
Three Months of Consecutive Growth Signals Economic Momentum
Marcus Lemonis takes CEO role at Bed Bath & Beyond with $25M cost-cutting plan and watch what industry experts are saying about his next move
SPX surges 34 points at open with shocking tech recovery, here’s what caused the unexpected Venezuela rally
November marked the third straight month of manufacturing expansion for Singapore’s economy. September saw 15.8% growth, followed by October’s revised 28.9% increase, and now November’s 14.3% gain. Despite moderating from October’s peak, the sustained expansion demonstrates the resilience of Singapore’s manufacturing sector amid global trade uncertainties. This manufacturing rebound has contributed to Singapore’s upgraded economic outlook for 2025.
The Asia-Pacific Economic Cooperation (APEC) region and global supply chains have benefited from Singapore’s strategic position. The sustained pharmaceutical production boosts reflect both local demand and re-export activity as companies position themselves for international markets.
Manufacturing Performance Metrics and Sector Breakdown
| Metric | November 2025 | October 2025 |
| Overall Output Growth (YoY) | +14.3% | +28.9% (revised) |
| Pharma Production Growth | +124.3% | +122.9% |
| Biomedical Cluster Growth | +79.3% | +89.8% |
| General Manufacturing (Jan-Nov YTD) | -8.8% | N/A |
Economic Development Board Confirms Strong Recovery Trajectory
The Economic Development Board (EDB) confirmed Singapore’s November manufacturing data showing 14.3% year-on-year growth. The agency’s official announcement highlighted the consistent performance of the biomedical manufacturing cluster as the primary growth driver. Excluding biomedical production, overall output contracted, underscoring how concentrated the manufacturing gains have become in the pharmaceutical and medical technology sectors.
Singapore’s manufacturing sector benefits from established regulatory frameworks and skilled workforce capabilities in pharmaceutical production. The city-state has become a preferred location for multinational pharmaceutical companies seeking to expand production capacity. Active pharmaceutical ingredient (API) manufacturing has particularly strengthened, supporting both domestic and regional pharmaceutical supply chains.
What Does This Growth Mean for Singapore’s Economic Future?
The sustained pharmaceutical sector boom raises important questions about Singapore’s manufacturing diversification. While biomedical growth is exceptional, the contraction in general manufacturing suggests the economy’s manufacturing recovery is not evenly distributed. The global trade environment continues to challenge traditional manufacturing, though the life sciences sector demonstrates remarkable resilience. Singapore’s ability to leverage this biomedical strength while revitalizing general manufacturing will determine broader economic health throughout 2026.
Sources
- The Straits Times – Singapore factory output growth reporting
- Economic Development Board – Official manufacturing performance data
- Trading Economics – Industrial production statistics and forecasts
Patrick Graham is a business and finance journalist translating Wall Street’s complexities into stories that matter to everyday readers. With extensive experience in financial journalism and economic analysis, this expert journalist provides sharp insights on market trends, corporate developments, and the economic forces affecting daily life. His reporting helps readers make sense of the business world’s biggest moves.